All Article articles
View all stories of the same content type.
-
ArticleGaelic Labs: Pharma is increasingly focused on supply chain security
General Manager Brian Morrissey discuss his company’s acquisition of fellow Beta-Lactam manufacturer Athlone Laboratories and its implications for an evolving industry.
-
ArticleTMSI: a novel, AI-driven alternative microbiological method for microorganism detection, enumeration and identification
Spore.Bio illustrates an AI-native, rapid microbiological method (RMM) that offers simultaneous viable quantitation and microbial identification capabilities suited to a range of applications including bioburden tests and environmental monitoring.
-
ArticleOptimising the downstream process in lentiviral vector manufacturing
Sartorius BIA Separations illustrates a promising alternative approach for efficient lentiviral vector purification that delivers a scalable, GMP-ready biomanufacturing solution.
-
ArticleThe implementation of biodiversity footprinting – examining supply chains
Carbon accounting is a well recognised means of assessing environmental impact in terms of greenhouse gas emissions, but the ecological effects from business practices are far broader. Dr Tara Garraty reveals how biodiversity footprinting serves to paint a more complete picture.
-
ArticleApplying AI to enhance drug formulation and development
AI/ML is not replacing formulation scientists or process engineers; it is just amplifying their expertise.
-
ArticleThe case for outsourcing water for injection
Essential for any medicine that must be sterile and safe for injection, ROIS’ Miguel Ángel Ortega Sánchez presents the case for outsourcing WFI production to a trusted partner.
-
ArticleAccelerating consistent, stable cell line development with targeted integration
Experts from WuXi Biologics explain how next-generation cell line development with targeted integration advances the field by enabling the production of clonal cell lines with predictable transgene copies at specific, predefined sites in the host genome.
-
ArticlePrecision medicine in epilepsy and brain health as a strategic investment
From genetic discovery to integrated care, Angelini Pharma’s Rafal Kaminski, (Chief Scientific Officer) celebrates International Epilepsy Day.
-
ArticleTerpenes in medicinal cannabis: a formulation challenge
Dean Hatt, Senior Toxicology Consultant at CRO Broughton, highlights the impact of cannabis compounds in pharmaceutical products.
-
ArticleFrom quantum to clinic: AI reshapes clinical trials
The burden of conducting clinical trials is a significant hurdle in drug discovery. Here, Dr Mark Lambrecht reveals the technological developments that are driving shifts in this space.
-
ArticleBioprocessing symposium to showcase biopharma and purification innovation
The three-day MSS2026 event takes place in September in Slovenia, with online attendance options also available.
-
Article
The future of pharma R&D leadership
People, not platforms, will define the next era of innovation, explain Chiesi’s Executive VP of R&D Diego Ardigò and Nick Petschek, EMEA Managing Director at Kotter.
-
ArticleReiThera on vaccines and remaining nimble around emerging threats
As vaccines are buffeted by political pressures, the CDMO discussed its growth approach and some of its key collaborations.
-
ArticleFujifilm's Lars Petersen on trust-based partnerships and a ‘people first’ culture
Named CEO of the Year at CPHI Frankfurt, the CDMO’s head talks about the type of company he and his team are building.
-
ArticleProven strategies for cleanroom and water system qualification success
The critical role of identification and documentation in contamination control.
-
ArticleHow to navigate expedited review pathways – a guide for biopharma companies
Experts from Quotient Sciences present a roadmap for moving novel drugs to market more quickly.
-
ArticleLiterature as data – using large language models to prioritise protein binding pockets
Here, Alan Nafiiev, CEO and founder of Receptor.AI, discusses the benefits of using large language models to integrate literature evidence and structural prediction to accelerate binding site identification.
-
ArticleA four-step way out of pharma manufacturing's asset management struggles
Here, Hexagon outlines a four-step plan to address silos and scale-up challenges, drawing on the experience of leading pharma firms like Pfizer.
-
ArticleA careful calibration: balancing small molecule needs and biologic innovation
CDMOs weigh up how to meet manufacturing demands across oral solid doses, monoclonal antibodies, ADCs and beyond.
-
ArticleCould a simple handle change your cleanroom contamination risk?
MBV AG addresses challenges in air monitoring and aseptic handling with MAS-100 Sirius®: a next‑generation active microbial air sampler created in close collaboration with pharmaceutical manufacturers and cleanroom experts.